Investor Presentation - First Six Months of 2021
25
Investor presentation
First six months of 2021
Sales growth of 12% at CER, driven by all therapy areas and in
particular the portfolio of GLP-1 treatments
Novo Nordisk reported quarterly sales
DKK
billion
31
40
35
CAGR¹: 7.2%
by therapy
Reported sales
Reported sales for the first six
months of 2021
Rare
endocrine
Other
Biopharm
Rare disorders
30
blood
disorders
1%
6%
25
(3.4%)¹
Obesity
8%
3.8%1
care
250
5%
20
2.9%¹
15
8.3%¹
10
5
0
Q2
Other
2011
Rare endocrine disorders
Rare blood disorders
Diabetes and Obesity care
Q2
2021
Sales of DKK 66.8 billion (5%)
Reported sales and growth breakdown for
the six months of 2021
Novo Nordisk®
Therapy
Sales
(MDKK)
Growth
Share of
growth
Total GLP-12
23,377
30%
77%
Long-acting insulin³
8,971
2%
2%
Premix insulin4
5,668
5%
4%
Fast-acting insulin 5
8,808
(1%)
(2%)
Human insulin
4,576
(3%)
(2%)
Total insulin
28,023
1%
2%
Other Diabetes care
1,919
(5%)
(1%)
Total Diabetes care
Obesity care?
53,319
11%
78%
3,543
34%
13%
Diabetes and Obesity care
56,862
13%
91%
80%
Rare blood disorders
5,401
11%
7%
Diabetes care
Rare endocrine disorders⁹
Other Biopharm 10
Biopharm
3,779
2%
1%
803
5%
1%
9,983
7%
9%
Total
66,845
12%
100%
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®, Rybelsus®; 3 Comprises TresibaⓇ, XultophyⓇ and Levemir®; 4 Comprises RyzodegⓇ and Novo MixⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ: 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises SaxendaⓇ and WegovyTM 8 Comprises NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, and EsperoctⓇ; 9 Comprises Norditropin®: 10 Primarily Vagifem® and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 5%; RefixiaⓇ and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation